ARRY-371797 (PF-07265803)
Phase 3Terminated 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Dilated Cardiomyopathy
Conditions
Dilated Cardiomyopathy, Lamin A/C Gene Mutation
Trial Timeline
Apr 17, 2018 → Oct 13, 2022
NCT ID
NCT03439514About ARRY-371797 (PF-07265803)
ARRY-371797 (PF-07265803) is a phase 3 stage product being developed by Pfizer for Dilated Cardiomyopathy. The current trial status is terminated. This product is registered under clinical trial identifier NCT03439514. Target conditions include Dilated Cardiomyopathy, Lamin A/C Gene Mutation.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03439514 | Phase 3 | Terminated |
Competing Products
10 competing products in Dilated Cardiomyopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Carvedilol + Metoprolol succinate + Metoprolol succinate + doxazosin | AstraZeneca | Approved | 85 |
| AZD0233 + AZD0233 Placebo | AstraZeneca | Phase 1 | 33 |
| AZD4063 | AstraZeneca | Phase 1 | 33 |
| ARRY-371797, p38 inhibitor, oral | Pfizer | Phase 2 | 51 |
| ARRY-371797, p38 inhibitor; oral | Pfizer | Phase 2 | 51 |
| danicamtiv | Bristol Myers Squibb | Phase 2 | 51 |
| Ixmyelocel-T | Vericel | Phase 2 | 47 |
| ixmyelocel-T | Vericel | Phase 2 | 47 |
| Ixmyelocel-T | Vericel | Phase 2 | 47 |
| talfirastide | Constant Therapeutics | Phase 2 | 44 |